Oncology · Urology
PREVAIL Model for Prostate Cancer Survival calculator
Enter the published formula inputs below to calculate and interpret this score.
Clinical inputs
Result
Anyone can run this calculator. Sign in to save, favourite, or send the result.
0
Low-risk group (0–3 risk variables)
Band: Low-risk group (0–3 risk variables)
Interpretation. Low-risk group (0–3 risk variables)
Suggested management. In the testing set, median overall survival in this group was not yet reached.
PREVAIL Model for Prostate Cancer Survival: 0 — Low-risk group (0–3 risk variables). Interpretation: Low-risk group (0–3 risk variables) What to do: In the testing set, median overall survival in this group was not yet reached. Inputs: PSA above 50 ng/mL: false; Time from diagnosis under 60 months: false; Albumin below 4.0 g/dL (40 g/L): false; Haemoglobin below 12.5 g/dL (125 g/L): false; Neutrophil-to-lymphocyte ratio 2.5 or higher: false; Any liver metastases: false; Pain score 2 or higher: false; LDH at or above the upper limit of normal: false; 10 or more bone metastases: false; Alkaline phosphatase at or above the upper limit of normal: false; Not receiving enzalutamide (placebo or natural history): false Source: Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29(11):2200-2207. DOI: 10.1093/annonc/mdy406. PMID: 30202945. Table 2 footnote risk variables: PSA >50 ng/ml, time from diagnosis <60 months, albumin <4.0 g/dl, haemoglobin <12.5 g/dl, NLR >=2.5, any liver metastases, pain score >=2, LDH >= ULN, >=10 bone metastases, ALP >= ULN, and placebo treatment (natural history). Patients are grouped by the number present at baseline: 0-3 low, 4-6 intermediate, 7-10 high risk; median overall survival in the testing set was not reached, 30.1 months and 16.5 months. The full 11-variable continuous risk score uses supplementary coefficients and is not reproduced here; the abstract's low/intermediate/high groups are tertiles of that continuous score and have different median survivals from these count-based Table 2 groups. (2018)
Ruqelo is AI and can make mistakes. Check important information.
Clinical inputs
- PSA above 50 ng/mL
- Time from diagnosis under 60 months
- Albumin below 4.0 g/dL (40 g/L)
- Haemoglobin below 12.5 g/dL (125 g/L)
- Neutrophil-to-lymphocyte ratio 2.5 or higher
- Any liver metastases
- Pain score 2 or higher
- LDH at or above the upper limit of normal
- 10 or more bone metastases
- Alkaline phosphatase at or above the upper limit of normal
- Not receiving enzalutamide (placebo or natural history)
Primary source
Armstrong AJ, Lin P, Higano CS, et al. Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer. Ann Oncol. 2018;29(11):2200-2207. DOI: 10.1093/annonc/mdy406. PMID: 30202945. Table 2 footnote risk variables: PSA >50 ng/ml, time from diagnosis <60 months, albumin <4.0 g/dl, haemoglobin <12.5 g/dl, NLR >=2.5, any liver metastases, pain score >=2, LDH >= ULN, >=10 bone metastases, ALP >= ULN, and placebo treatment (natural history). Patients are grouped by the number present at baseline: 0-3 low, 4-6 intermediate, 7-10 high risk; median overall survival in the testing set was not reached, 30.1 months and 16.5 months. The full 11-variable continuous risk score uses supplementary coefficients and is not reproduced here; the abstract's low/intermediate/high groups are tertiles of that continuous score and have different median survivals from these count-based Table 2 groups. (2018)
View source